Zivelonghi Carlo, Verheye Stefan
Cardiovascular Center Zeikenhuisnetwerk Antwerpen (ZNA)-Middelheim, Antwerp, Belgium.
Heart Int. 2020 Aug 4;14(1):29-33. doi: 10.17925/HI.2020.14.1.29. eCollection 2020.
The coronary sinus reducer represents an emerging therapeutic option for patients suffering from chronic refractory angina. Current data indicate that the population suffering from angina symptoms despite maximal medical therapy and maximal achievable revascularisation - surgical or percutaneous - is constantly increasing. Also, the clinical outcome for these patients is strongly affected by the lack of adequate treatment, the occurrence of adverse events and the need for repeated hospitalisation. Growing evidence supports the clinical benefits of the coronary sinus reducer in relieving angina symptoms in this specific population, with emerging evidence of reduction in myocardial ischaemia following the implantation of the coronary sinus reducer. In this review, we provide an up-to-date description of the role of this relatively new device in the treatment of refractory angina, focusing not only on symptom relief but also on the increasing data that supports objective improvements in myocardial ischaemia.
冠状静脉窦减压器为慢性顽固性心绞痛患者提供了一种新的治疗选择。目前的数据表明,尽管接受了最大程度的药物治疗以及可实现的最大程度血运重建(手术或经皮介入),仍有心绞痛症状的患者数量在不断增加。此外,这些患者的临床结局受到治疗不足、不良事件的发生以及反复住院需求的严重影响。越来越多的证据支持冠状静脉窦减压器对这一特定人群缓解心绞痛症状的临床益处,并且有新证据表明植入冠状静脉窦减压器后心肌缺血有所减轻。在本综述中,我们对这种相对较新的装置在顽固性心绞痛治疗中的作用进行了最新描述,不仅关注症状缓解,还关注支持心肌缺血客观改善的越来越多的数据。